BACKGROUNDRecombinant human GH, first licensed to treat GH deficiency (GHD) in children in 1985, is now approved to treat GHD in adults and other paediatric conditions associated with growth impairment. Hence, hundreds of thousands of children and adults have received GH treatment over the past 3 decades.Clinical trials have demonstrated the efficacy and safety of GH treatment. The short‐term safety profile is considered to be good; the incidence of adverse events (AEs) is lower than expected based on patients with natural GH excess (acromegaly). The long‐term safety profile of GH has been well documented by postmarketing registries established by the major manufacturers following GH approval.In 2007, preliminary data from the French cohort of the Safety and Appropriateness of Growth hormone treatments in Europe (SAGhE) study suggested a link between childhood GH treatment and premature death and from a second report, between GH treatment and stroke. However, preliminary data from Belgium, the Netherlands and Sweden (2543 patients) showed no excess deaths due to cancer or cardiovascular disease. Although the validity of the French cohort study has since been questioned, it has nevertheless brought the long‐term safety profile of GH to the forefront. The SAGhE study collected data from cohorts of
Clinical Endocrinology – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud